(Reuters) – Novo Nordisk said on Tuesday the U.S. FDA has approved its diabetes drug Ozempic to reduce the risk of worsening kidney disease and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shilpi Majumdar)
